Equity Overview
Price & Market Data
Price: $7.12
Daily Change: +$0.484 / 6.80%
Range: $6.34 - $7.54
Market Cap: $4,185,690
Volume: 28,529
Performance Metrics
1 Week: 29.90%
1 Month: -31.08%
3 Months: -46.62%
6 Months: -72.96%
1 Year: -69.19%
YTD: -68.75%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.